tiprankstipranks
NovoCure Ltd. (NVCR)
NASDAQ:NVCR
US Market
NVCR
NovoCure
RESEARCH TOOLSreports
Want to see NVCR full AI Analyst Report?

NovoCure (NVCR) Stock Forecast & Price Target

1,585 Followers
See the Price Targets and Ratings of:

NVCR Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
Based on 6 analysts giving stock ratings to
NovoCure
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NVCR Stock 12 Month Forecast

Average Price Target

$26.17
▲(103.95% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for NovoCure in the last 3 months. The average price target is $26.17 with a high forecast of $48.00 and a low forecast of $17.00. The average price target represents a 103.95% change from the last price of $12.83.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","19":"$19","29":"$29","39":"$39","49":"$49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.166666666666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,19,29,39,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.62,19.033846153846156,21.447692307692307,23.861538461538462,26.275384615384617,28.68923076923077,31.103076923076927,33.51692307692308,35.93076923076923,38.34461538461539,40.758461538461546,43.1723076923077,45.58615384615385,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.62,17.354358974358977,18.08871794871795,18.823076923076925,19.557435897435898,20.291794871794874,21.026153846153846,21.760512820512822,22.494871794871795,23.22923076923077,23.963589743589743,24.69794871794872,25.432307692307695,{"y":26.166666666666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.62,16.64923076923077,16.67846153846154,16.70769230769231,16.736923076923077,16.76615384615385,16.795384615384616,16.824615384615385,16.853846153846153,16.883076923076924,16.912307692307692,16.94153846153846,16.970769230769232,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$48.00Average Price Target$26.17Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on NVCR
Larry Biegelsen
Wells Fargo
Wells Fargo
$13.5→$17
Hold
32.50%
Upside
Assigned
05/04/26
Novocure price target raised to $17 from $13.50 at Wells FargoNovocure price target raised to $17 from $13.50 at Wells Fargo
Wedbush Analyst forecast on NVCR
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$18
Hold
40.30%
Upside
Reiterated
05/01/26
Wedbush Remains a Hold on NovoCure (NVCR)
H.C. Wainwright Analyst forecast on NVCR
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$48
Buy
274.12%
Upside
Reiterated
05/01/26
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Verano Holdings (VRNO)
Evercore ISI Analyst forecast on NVCR
Vijay Kumar
Evercore ISI
Evercore ISI
$16→$20
Buy
55.88%
Upside
Reiterated
05/01/26
Novocure price target raised to $20 from $16 at Evercore ISINovocure price target raised to $20 from $16 at Evercore ISI
Piper Sandler Analyst forecast on NVCR
Jason Bednar
Piper Sandler
Piper Sandler
$27
Buy
110.44%
Upside
Reiterated
03/25/26
Analysts Conflicted on These Healthcare Names: TELA Bio (NASDAQ: TELA), NovoCure (NASDAQ: NVCR) and Incyte (NASDAQ: INCY)
Ladenburg Thalmann & Co. Analyst forecast on NVCR
Unknown Analyst
Ladenburg Thalmann & Co.
Not Ranked
Ladenburg Thalmann & Co.
$27
Buy
110.44%
Upside
Reiterated
02/27/26
Ladenburg Thalmann & Co. Remains a Buy on NovoCure (NVCR)
Leerink Partners Analyst forecast on NVCR
Jonathan Chang
Leerink Partners
Leerink Partners
$24
Buy
87.06%
Upside
Reiterated
01/13/26
Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Henry Schein (NASDAQ: HSIC) and NovoCure (NASDAQ: NVCR)
J.P. Morgan Analyst forecast on NVCR
Jessica Fye
J.P. Morgan
J.P. Morgan
$25→$23
Hold
79.27%
Upside
Reiterated
10/27/25
Novocure price target lowered to $23 from $25 at JPMorganNovocure price target lowered to $23 from $25 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on NVCR
Larry Biegelsen
Wells Fargo
Wells Fargo
$13.5→$17
Hold
32.50%
Upside
Assigned
05/04/26
Novocure price target raised to $17 from $13.50 at Wells FargoNovocure price target raised to $17 from $13.50 at Wells Fargo
Wedbush Analyst forecast on NVCR
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$18
Hold
40.30%
Upside
Reiterated
05/01/26
Wedbush Remains a Hold on NovoCure (NVCR)
H.C. Wainwright Analyst forecast on NVCR
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$48
Buy
274.12%
Upside
Reiterated
05/01/26
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Verano Holdings (VRNO)
Evercore ISI Analyst forecast on NVCR
Vijay Kumar
Evercore ISI
Evercore ISI
$16→$20
Buy
55.88%
Upside
Reiterated
05/01/26
Novocure price target raised to $20 from $16 at Evercore ISINovocure price target raised to $20 from $16 at Evercore ISI
Piper Sandler Analyst forecast on NVCR
Jason Bednar
Piper Sandler
Piper Sandler
$27
Buy
110.44%
Upside
Reiterated
03/25/26
Analysts Conflicted on These Healthcare Names: TELA Bio (NASDAQ: TELA), NovoCure (NASDAQ: NVCR) and Incyte (NASDAQ: INCY)
Ladenburg Thalmann & Co. Analyst forecast on NVCR
Unknown Analyst
Ladenburg Thalmann & Co.
Not Ranked
Ladenburg Thalmann & Co.
$27
Buy
110.44%
Upside
Reiterated
02/27/26
Ladenburg Thalmann & Co. Remains a Buy on NovoCure (NVCR)
Leerink Partners Analyst forecast on NVCR
Jonathan Chang
Leerink Partners
Leerink Partners
$24
Buy
87.06%
Upside
Reiterated
01/13/26
Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Henry Schein (NASDAQ: HSIC) and NovoCure (NASDAQ: NVCR)
J.P. Morgan Analyst forecast on NVCR
Jessica Fye
J.P. Morgan
J.P. Morgan
$25→$23
Hold
79.27%
Upside
Reiterated
10/27/25
Novocure price target lowered to $23 from $25 at JPMorganNovocure price target lowered to $23 from $25 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NovoCure

3 Months
Jason BednarPiper Sandler
Success Rate
17/29 ratings generated profit
59%
Average Return
+9.60%
Copying Jason Bednar's trades and holding each position for 3 Months would result in 58.62% of your transactions generating a profit, with an average return of +9.60% per trade.
1 Year
Jason BednarPiper Sandler
Success Rate
13/29 ratings generated profit
45%
Average Return
+9.60%
Copying Jason Bednar's trades and holding each position for 1 Year would result in 44.83% of your transactions generating a profit, with an average return of +9.60% per trade.
2 Years
Emily BodnarH.C. Wainwright
Success Rate
10/22 ratings generated profit
45%
Average Return
-7.42%
Copying Emily Bodnar's trades and holding each position for 2 Years would result in 45.45% of your transactions generating a profit, with an average return of -7.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVCR Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
6
13
14
11
5
Buy
1
1
1
0
1
Hold
3
5
4
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
19
19
14
9
In the current month, NVCR has received 6 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. NVCR average Analyst price target in the past 3 months is 26.17.
Each month's total comprises the sum of three months' worth of ratings.

NVCR Financial Forecast

NVCR Earnings Forecast

Next quarter’s earnings estimate for NVCR is -$0.33 with a range of -$0.40 to -$0.23. The previous quarter’s EPS was -$0.62. NVCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NVCR has Performed in-line its overall industry.
Next quarter’s earnings estimate for NVCR is -$0.33 with a range of -$0.40 to -$0.23. The previous quarter’s EPS was -$0.62. NVCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year NVCR has Performed in-line its overall industry.

NVCR Sales Forecast

Next quarter’s sales forecast for NVCR is $172.72M with a range of $168.22M to $174.80M. The previous quarter’s sales results were $174.06M. NVCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NVCR has Performed in-line its overall industry.
Next quarter’s sales forecast for NVCR is $172.72M with a range of $168.22M to $174.80M. The previous quarter’s sales results were $174.06M. NVCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year NVCR has Performed in-line its overall industry.

NVCR Stock Forecast FAQ

What is NVCR’s average 12-month price target, according to analysts?
Based on analyst ratings, NovoCure Ltd.’s 12-month average price target is 26.17.
    What is NVCR’s upside potential, based on the analysts’ average price target?
    NovoCure Ltd. has 103.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NVCR a Buy, Sell or Hold?
          NovoCure Ltd. has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
            What is NovoCure Ltd.’s price target?
            The average price target for NovoCure Ltd. is 26.17. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $48.00 ,the lowest forecast is $17.00. The average price target represents 103.95% Increase from the current price of $12.83.
              What do analysts say about NovoCure Ltd.?
              NovoCure Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of NVCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.